Last reviewed · How we verify
ABT-301
At a glance
| Generic name | ABT-301 |
|---|---|
| Also known as | MPT0E028, Imofinostat |
| Sponsor | Anbogen Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-301 CI brief — competitive landscape report
- ABT-301 updates RSS · CI watch RSS
- Anbogen Therapeutics, Inc. portfolio CI